Glucagon Market is Anticipated to Increase at a Stable CAGR over the Forecast Period (2023 to 2029)

The global glucagon market is anticipated to grow at a considerable CAGR of 5.9% during the forecast period. Glucagon is a metabolic hormone that increases the glucose level in the blood with the support of the liver which rapidly converts glycogen into glucose. The glucagon is secreted by the pancreas, which is further converted into glucose and released in the blood. It is basically used in the treatment of disorders such as low blood sugar and others. The primary factor attributing to the growth of the market includes the rising government activities such as FDA approvals and others across the globe. The globe has witnessed a considerable increase in the number of diabetic patients, which has increased the requirement for improved drugs for treatment. Hence, the government of several countries is pushing pharmaceutical companies and drug manufacturers to develop new and enhanced glucagon, which directly propels the growth of the market.

For instance, in December 2020, the US FDA approved the first generic of glucagon for injection USP, 1 mg/vial packaged in an emergency kit, for the treatment of severe hypoglycemia. Hypoglycemia is a condition of the very low blood sugar level, which primarily occurs in patients with diabetes mellitus. The drug is also indicated as a diagnostic aid in the radiologic examination of the stomach, duodenum, small bowel, and colon when reduced ability to move.

To Request a Sample of our Report on Glucagon Market: https://www.omrglobal.com/request-sample/glucagon-market

Market Coverage

• The market number available for - 2022-2030

• Base year- 2022

• Forecast period- 2023-2030

Segment Covered-

• By Product Type

• By Application

• By Distribution Channel

Regions Covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

• Competitive Landscape- including Amgen Inc., Pfizer, Inc., Lilly USA, LLC, Xeris Biopharma Holdings, Inc., and others.

Glucagon Market Report Segment

By Product Type

• Injectable

• Nasal

By Application

• Emergency Kits

• General Use

• Diagnostics and Motility

• Others (Cardiogenic Shock)

By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

A full Report of Glucagon Market is Available @ https://www.omrglobal.com/industry-reports/glucagon-market

Glucagon Market Report Segment by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

• Latin America

• Middle East and Africa

Company Profiles

• Amgen Inc.

• Amphastar Pharmaceuticals

• Avalon Pharma Pvt. Ltd.

• Bachem Holding AG

• Fresenius SE & Co. KGaA

• FUJIFILM Holdings Corp.

• Lilly USA, LLC

• Novo Nordisk A/S

• Pfizer Inc.

• Svar Life Science AB

• Taj Pharmaceuticals Ltd. (Taj Group)

• Xeris Biopharma Holdings, Inc.

• Zealand Pharma A/S

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/glucagon-market

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.